Unveiling the future of cell and gene therapies in the UK
In recent years, cell and gene therapies have been advancing at lightning speed, offering new hope to…
Twitter outputted an error:
Invalid or expired token..
Invalid or expired token..
New Alzheimer’s treatment ‘lecanemab’ approved for use in the US
LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.
Catriona Crombie talks to Rare Revolution about LifeArc’s investment of more than £100 million into rare disease research by 2030
Catriona discusses why LifeArc is well placed to help overcome some of the obstacles in rare disease research
How LifeArc’s Neurodegeneration Translational Challenge is leading the charge against Motor Neurone Disease
June 21st is Global MND Awareness Day, a day to raise worldwide awareness of MND (Motor Neurone Disease) and to stand in solidarity with the MND/ALS community.
Meet our industrial placement students – class of 2023
Find out what this year's cohort of industrial placement students gained from the experience.
Translational research into children’s rare diseases enters 5th year of collaborative funding
Accelerating research that will have a significant impact on the treatment of children and young people
Talking to FLIER future leaders about learning from COVID-19 and the power of collaboration
The Future Leaders in Innovation Enterprise and Research is a two-year programme for emerging leaders in science, technology and medicine.
Highlights from Illumina for Startups Summit 2023
Key takeaways from the summit for entrepreneurs, founders, investors and industry leaders from around the world.
International Women’s Day 2023
Tips on career advancement, from some of LifeArc’s incredible women